Printer Friendly

Cytori names Gregg Lapointe to board.

M2 EQUITYBITES-April 4, 2017-Cytori names Gregg Lapointe to board

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Therapeutics company Cytori Therapeutics Inc (NasdaqCM:CYTX) reported on Monday the addition of Gregg Lapointe as an independent director to its board of directors with effect from 31 March 2017.

Currently, Lapointe is a co-founder and CEO of Cerium Pharmaceuticals; a member of the board of directors of SciClone Pharmaceuticals, Soligenix and Immunocellular Therapeutics; and a member of the board of trustees of the Keck Graduate Institute of Applied Life Sciences.

Previously, Lapointe was the CEO at Sigma-Tau Pharmaceuticals, held various roles at AstenJohnson, Medical Plastic Devices Inc and Ingram & Bell Meditron, senior manager at Zittrer Siblin Stein Levine, as well as a chartered accountant and audit manager at Price Waterhouse at the start of his career.

Earlier in his career, Lapointe was a board member and chair of the Rare Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as a member of the board of directors of Questcor Pharmaceuticals and Raptor Pharmaceutical Corp.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 4, 2017
Words:187
Previous Article:Five John Hancock closed-end funds announce distributions for April 2017.
Next Article:Marina Biotech signs manufacturing agreement for IT-102 FDC bi-layer tablet.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters